A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages

A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages

Objectives: Interleukin (IL)-6 inhibitors are administered to treat patients hospitalized with COVID-19. In 2021, due to shortages, different dosing regimens of tocilizumab, and a switch to sarilumab, were consecutively implemented. Using real-world data, we compare the effectiveness of these IL-6 i...

Full description

Bibliographic Details
Main Authors: Maaike C. Swets, Rob J. Moss, Flip Kor, Doranne Hilarius, Dirk Jan A.R. Moes, Willemijn EM Berkhout, Leon M. van den Toorn, Niels C. Gritters van den Oever, Renee de Valk, Frits R. Rosendaal, Nicole Hunfeld, Geert H. Groeneveld, Mark G.J. de Boer
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:International Journal of Infectious Diseases
Subjects:
IL-6 inhibitor
COVID-19
SARS-CoV-2
Tocilizumab
Sarilumab
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971223000413

Internet

http://www.sciencedirect.com/science/article/pii/S1201971223000413

Similar Items